Tempus targets $1.595B-$1.605B 2026 revenue as it outlines 2028 $400M uplift tied to xT CDx and xF (NASDAQ:TEM)
· seekingalpha.com
Tempus AI (TEM) Q2 2026 earnings call recap: 22% revenue growth, FDA xT CDx approval, xF/MRD catalysts, raised 2026 guide, Personalis deal.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...